TSXV:CVM.H - Post by User
Post by
Looneytuneson Oct 08, 2019 6:23pm
161 Views
Post# 30209382
Comparison
ComparisonRunning a comparison to a download of the presentation I took in May . .notes
Slide 14 - Potential practice economics = Estimated monthly revenue based on 100 scans has fallen by $2,000 (to $12,500 from $14,500 - $16,500) and estimated annual revenue fallen to £150,000 from $174,000). This doesnt add up as the cost per test, monthly lease cost and retail proce of disposables remains unchanged.
Slide 15 - Care office visits : the number of visits has been updated to refelct 2016 figures - earlier presentation based on 2015.
Slide 16 - Reimbursment - Recommended cost of each test has been changed from $75 - $125 -to $125
Slide 18 has become a sales projections slide
Slide 20 - indicates that the Sales and Marketing plan is now complete, Device Leasing has now become Device Financing but is still ticked as complete, and FDA Clearance has become Resubmit to FDA with clearance 2H 2020 (which indicates to me that the full 130 day review period will staret again upon resubmission.
Slide 21 - Capitalisation - 72% still remains in public hands but the 23% in escrow has now moved to Insiders.
Slide 23: new slide relating to first year revenue
Slide 24: Ongoing international negotiations slide has reappeared - it was in earlier versions but was dropped early this year.
. . . . and thats it. The presentation asserts that FDA submission will happen in January but please don't hold your breath as there is no indication that the steps needed to achieve this will either be done in time, or the CVR Global has the funds to pay for them.